Skip to main content
Top
Published in: BMC Cancer 1/2019

Open Access 01-12-2019 | Computed Tomography | Case report

Abscopal effect of radiation on multiple lung metastases of lung adenocarcinoma: a case report

Authors: Aoi Kuroda, Takaya Tabuchi, Eri Iwami, Kotaro Sasahara, Tatsu Matsuzaki, Takahiro Nakajima, Yuki Tsutsumi, Keisuke Eguchi, Takeshi Terashima

Published in: BMC Cancer | Issue 1/2019

Login to get access

Abstract

Background

Abscopal effect is the out-of-field response to localized irradiation therapy that results in systemic antitumorigenic effects such as the regression of a tumor distant from the target site.

Case presentation

A 76-year-old woman was diagnosed with pulmonary adenocarcinoma (cT1bN0M0 stage IA), and right upper lobectomy was performed in November 2015. The pathological stage was pT1bN2M0 stage IIIA. Genomic analysis revealed an EGFR mutation. Immunohistochemical analysis revealed a programmed death-ligand 1 tumor proportion score of < 1%. The patient was under watchful observation without adjuvant chemotherapy. Multiple mediastinal and right hilar lymph node metastases were found in February 2018. Radiation therapy at a total dose of 60.0 Gy distributed in 30 fractions was performed over a period of 6 weeks. A computed tomography (CT) scan performed 6 weeks after irradiation therapy showed a reduction in lymph node metastases. However, left hilar and right supraclavicular lymph node metastases and multiple pulmonary metastases were newly observed outside of the irradiation field. A CT scan performed 6 weeks later showed a dramatic complete disappearance of the previously observed pulmonary metastases. No chemotherapy was administered during the period.

Conclusion

This was a case of abscopal effect: irradiation of the mediastinum resulted in the disappearance of multiple pulmonary metastases in both lungs.
Literature
1.
go back to reference Mole RH. Whole body irradiation—radiobiology or medicine? Br J Radiol. 1953;26:234–41.CrossRef Mole RH. Whole body irradiation—radiobiology or medicine? Br J Radiol. 1953;26:234–41.CrossRef
2.
go back to reference Brix N, Tiefenthaller A, Anders H, Belka C, Lauber K. Abscopal, immunological effects of radiotherapy: narrowing the gap between clinical and preclinical experiences. Immunol Rev. 2017;280:249–79.CrossRef Brix N, Tiefenthaller A, Anders H, Belka C, Lauber K. Abscopal, immunological effects of radiotherapy: narrowing the gap between clinical and preclinical experiences. Immunol Rev. 2017;280:249–79.CrossRef
3.
go back to reference Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res. 2013;1:365–72.CrossRef Golden EB, Demaria S, Schiff PB, Chachoua A, Formenti SC. An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer. Cancer Immunol Res. 2013;1:365–72.CrossRef
4.
go back to reference Britschgi C, Riesterer O, Burger IA, Guckenberger M, Curioni-Fontecedro A. Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer. Radiat Oncol. 2018;13:102.CrossRef Britschgi C, Riesterer O, Burger IA, Guckenberger M, Curioni-Fontecedro A. Report of an abscopal effect induced by stereotactic body radiotherapy and nivolumab in a patient with metastatic non-small cell lung cancer. Radiat Oncol. 2018;13:102.CrossRef
5.
go back to reference Cong Y, Shen G, Wu S, Hao R. Abscopal regression following SABR for non-small-cell-lung cancer: a case report. Cancer Biol Ther. 2017;18:1–3.CrossRef Cong Y, Shen G, Wu S, Hao R. Abscopal regression following SABR for non-small-cell-lung cancer: a case report. Cancer Biol Ther. 2017;18:1–3.CrossRef
6.
go back to reference Siva S, Callahan J, Macmanus MP, Martin O, Hicks RJ, Ball DL. Asbcopal effects after conventional and stereotactic lung irradiation of non-small-cell lung cancer. J Thorac Oncol. 2013;8:e71–2.CrossRef Siva S, Callahan J, Macmanus MP, Martin O, Hicks RJ, Ball DL. Asbcopal effects after conventional and stereotactic lung irradiation of non-small-cell lung cancer. J Thorac Oncol. 2013;8:e71–2.CrossRef
7.
go back to reference Hekimoglu E, Kara HV, Demirkaya A, Turna A. Vanishing a primary lung carcinoma following irradiation of cranial metastasis: “the abscopal effect”. Turk J Thorac Cardiovasc Surg. 2017;25:294–7.CrossRef Hekimoglu E, Kara HV, Demirkaya A, Turna A. Vanishing a primary lung carcinoma following irradiation of cranial metastasis: “the abscopal effect”. Turk J Thorac Cardiovasc Surg. 2017;25:294–7.CrossRef
8.
go back to reference Rees GJG, Ross CMD. Abscopal regression following radiotherapy for adenocarcinoma. Br J Radiol. 1983;56:63–6.CrossRef Rees GJG, Ross CMD. Abscopal regression following radiotherapy for adenocarcinoma. Br J Radiol. 1983;56:63–6.CrossRef
9.
go back to reference Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 2015;41:503–10.CrossRef Reynders K, Illidge T, Siva S, Chang JY, De Ruysscher D. The abscopal effect of local radiotherapy: using immunotherapy to make a rare event clinically relevant. Cancer Treat Rev. 2015;41:503–10.CrossRef
10.
go back to reference Tang C, Welsh JW, De Groot P, Massarelli E, Chang JY, Hess KR, et al. Ipilimumab with stereotactic ablative radiation therapy: phase I results and immunologic correlates from peripheral T cells. Clin Cancer Res. 2017;23:1388–96.CrossRef Tang C, Welsh JW, De Groot P, Massarelli E, Chang JY, Hess KR, et al. Ipilimumab with stereotactic ablative radiation therapy: phase I results and immunologic correlates from peripheral T cells. Clin Cancer Res. 2017;23:1388–96.CrossRef
11.
go back to reference Pilones KA, Kawashima N, Yang AM, Babb JS, Formenti SC, Demaria S. Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade. Clin Cancer Res. 2009;15:597–606.CrossRef Pilones KA, Kawashima N, Yang AM, Babb JS, Formenti SC, Demaria S. Invariant natural killer T cells regulate breast cancer response to radiation and CTLA-4 blockade. Clin Cancer Res. 2009;15:597–606.CrossRef
12.
go back to reference Wang R, Zhou T, Liu W, Zuo L. Molecular mechanism of bystander effects and related abscopal/ cohort effects in cancer therapy. Oncotarget. 2018;9:18637–47.PubMedPubMedCentral Wang R, Zhou T, Liu W, Zuo L. Molecular mechanism of bystander effects and related abscopal/ cohort effects in cancer therapy. Oncotarget. 2018;9:18637–47.PubMedPubMedCentral
13.
go back to reference Liu Y, Dong Y, Kong L, Shi F, Zhu H, Yu J. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol. 2018;11:104.CrossRef Liu Y, Dong Y, Kong L, Shi F, Zhu H, Yu J. Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. J Hematol Oncol. 2018;11:104.CrossRef
14.
go back to reference Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. New Engl J Med. 2017;377:1919–29.CrossRef Antonia SJ, Villegas A, Daniel D, Vicente D, Murakami S, Hui R, et al. Durvalumab after chemoradiotherapy in stage III non–small-cell lung cancer. New Engl J Med. 2017;377:1919–29.CrossRef
Metadata
Title
Abscopal effect of radiation on multiple lung metastases of lung adenocarcinoma: a case report
Authors
Aoi Kuroda
Takaya Tabuchi
Eri Iwami
Kotaro Sasahara
Tatsu Matsuzaki
Takahiro Nakajima
Yuki Tsutsumi
Keisuke Eguchi
Takeshi Terashima
Publication date
01-12-2019
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2019
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/s12885-019-5566-8

Other articles of this Issue 1/2019

BMC Cancer 1/2019 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine